Fig. 5 | Cellular & Molecular Immunology

Fig. 5

From: Mesenchymal stromal cells counteract with age-related immune decline and enhance vaccine efficacy by modulating endogenous splenic marginal reticular cells in elderly models

Fig. 5The alternative text for this image may have been generated using AI.

VEGFA is a potential functional molecule by which MSCs promote MRC regeneration. A The top 10 ligands were screened and ranked via bulk RNA sequencing data from MSCs in vitro and those distributed in aged spleens. B Relative VEGFA mRNA expression was detected through RT‒PCR validation in the MSCNC, MSCVEGFA-KD1, MSCVEGFA-KD2, and MSCVEGFA-KD3 groups (n = 5). C Flow cytometry analysis of splenic MRC proliferation (CD45-CD31-Ter119-MAdCAM-1+KI-67+) in the Ctrl, MSCNC, MSCVEGFA-KD1, and MSCVEGFA-KD2 groups; n = 3 mice per group. D Vehicle (Ctrl), nonsense control MSC (MSCNC) or VEGFA-knockdown MSC (MSCVEGFA-KD) were administered to aged BALB/C mice (>18 months old), which were analyzed 28 days later (E, F) or then immunized with OVA (GJ). E Representative immunofluorescence staining of splenic stromal cells (PDGFRβ+, fuchsia) in the control, MSCNC, MSCVEGFA-KD1, and MSCVEGFA-KD2 groups. Scale bars: 100 μm. F Statistical analysis of the proportion of splenic stromal cells in the Ctrl, MSCNC, MSCVEGFA-KD1, and MSCVEGFA-KD2 groups; n = 3 mice per group. G Flow cytometry analysis of splenic germinal center B-cell populations (B220+IgD-GL7+) 28 days after OVA immunization in the control (OVA Ctrl), MSCNC + OVA, MSCVEGFA-KD1 + OVA, and MSCVEGFA-KD2 + OVA groups. H Representative immunofluorescence staining of follicular B lymphocytes (IgD+, fuchsia), germinal centers (GL-7+, green), and DAPI (blue) in the OVA Ctrl, MSCNC + OVA, MSCVEGFA-KD1 + OVA, and MSCVEGFA-KD groups; scale bars: 70 μm. I Statistical analysis of the splenic GC area (GL-7+) and GL-7+ RawIntden population in the OVA Ctrl, MSCNC + OVA, MSCVEGFA-KD1 + OVA and MSCVEGFA-KD2 + OVA groups; n = 3 mice per group. J Titers of serum soluble ovalbumin-specific IgG1 antibodies after 28 days of immunization in the OVA Ctrl, MSCNC + OVA, MSCVEGFA-KD1 + OVA and MSCVEGFA-KD2 + OVA groups; n = 4 mice per group. K Recombinant VEGFA was administered to aged BALB/C mice (>18 months old), and the results were analyzed 3 days later (L‒N). L Flow cytometry analysis of splenic MRC proliferation (CD45-CD31-Ter119-MAdCAM-1+KI-67+) in the vehicle (control) or recombinant VEGFA delivery (rVEGFA) groups after 3 days; n = 3 mice per group. (M) Representative immunofluorescence images of splenic MRCs (MAdCAM-1+, fuchsia), Ki-67 (green), and DAPI (gray) in the control and rVEGFA groups; scale bars: 5 μm. N Statistical analysis of splenic MRC proliferation in the control and rVEGFA groups; n = 5 mice per group. O Recombinant VEGFA was administered to aged BALB/C mice (>18 months old), and the results were analyzed 28 days later (PR) or after ovalbumin immunization (SV). P Representative flow cytometry of splenic stromal cells (CD45-CD31-Ter119-PDGFRβ+) in the control and rVEGFA groups. O Statistical analysis of the proportion of splenic stromal cells in the control and rVEGFA groups; n = 3 mice per group. R Statistical analysis of splenic stromal cell counts in the control and rVEGFA groups; n = 3 mice per group. S Flow cytometry analysis of splenic germinal center B-cell populations (B220+IgDGL7+) in the control (OVA Ctrl) and recombinant VEGFA groups 28 days before OVA immunization (rVEGFA +OVA); n = 3 mice per group. T Representative immunofluorescence staining of B lymphocytes (B220+, red) and germinal centers (PNA+, green) in the OVA Ctrl and rVEGFA +OVA groups; scale bars: 50 μm. U Statistical analysis of the splenic GC area (PNA+) in the OVA Ctrl and rVEGFA +OVA groups; n = 4 per group. V Titers of serum soluble ovalbumin-specific IgG1 antibodies after 28 days of OVA immunization in the groups of no immunization (Control), sham control (OVA Ctrl), and recombinant VEGFA administration 28 days before OVA immunization (rVEGFA +OVA), n = 4 mice per group. The data represent the means ± SEMs of three independent experiments. In (C, F, G, I, J), statistical significance was determined via one-way ANOVA with a multiple comparison test. In (L, N, Q, R, S, U, V), statistical significance was determined via a two-tailed unpaired t-test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. ns not significant

Back to article page